Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -263.43M | -252.85M | -15.95M | -20.92M | -58.22M |
| Total Depreciation and Amortization | 24.64M | 31.67M | 31.78M | 31.66M | 32.19M |
| Total Amortization of Deferred Charges | 19.98M | 19.11M | 18.58M | 17.78M | 17.35M |
| Total Other Non-Cash Items | 208.35M | 198.92M | -32.40M | -29.10M | -4.33M |
| Change in Net Operating Assets | -16.69M | -10.83M | -3.91M | -10.77M | -1.29M |
| Cash from Operations | -27.15M | -13.98M | -1.90M | -11.35M | -14.31M |
| Capital Expenditure | -264.00K | -264.00K | -220.00K | -27.00K | -97.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 123.00K | 0.00 | 0.00 |
| Cash from Investing | -264.00K | -264.00K | -97.00K | -27.00K | -97.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -2.00K | 188.00K | 1.40M | 1.23M | 701.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | 1.00K | 0.00 | 0.00 |
| Net Change in Cash | -27.42M | -14.06M | -599.00K | -10.14M | -13.70M |
